GIM
CTMX icon

Granahan Investment Management’s CytomX Therapeutics CTMX Stock Holding History

Granahan Investment Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-279,218
Closed -$1.83M – 195
2020
Q4 		$1.83M Sell
279,218
-50,338
-15% -$360K 0.04% 177
2020
Q3 		$2.19M Sell
329,556
-28,566
-8% -$212K 0.07% 147
2020
Q2 		$2.98M Buy
358,122
+92,449
+35% +$859K 0.11% 131
2020
Q1 		$2.04M Buy
265,673
+111,855
+73% +$780K 0.11% 130
2019
Q4 		$1.28M Buy
153,818
+421
+0.3% +$2.84K 0.06% 152
2019
Q3 		$1.13M Buy
153,397
+6,174
+4% +$60.9K 0.06% 154
2019
Q2 		$1.65M Sell
147,223
-9,168
-6% -$96.1K 0.08% 152
2019
Q1 		$1.68M Sell
156,391
-7,156
-4% -$106K 0.09% 157
2018
Q4 		$2.47M Sell
163,547
-3,541
-2% -$52.5K 0.17% 119
2018
Q3 		$3.09M Buy
167,088
+4,584
+3% +$104K 0.17% 125
2018
Q2 		$3.71M Sell
162,504
-88
-0.1% -$2.25K 0.22% 117
2018
Q1 		$4.63M Buy
162,592
+71,448
+78% +$2.04M 0.33% 97
2017
Q4 		$1.92M Buy
+91,144
New +$1.89M 0.15% 146

Other funds holding CTMX

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Granahan Investment Management's CTMX Position: Q1 2021 in Review

Granahan Investment Management sold out of CytomX Therapeutics (CTMX) in Q1 2021, closing a stake of 279,218 shares — an estimated $1.83M sold.

Granahan Investment Management first reported a position in CTMX in Q4 2017 and held it in 13 quarters. The position peaked at $4.63M in Q1 2018. 126 funds tracked by Wall St. Rank hold CTMX as of Q1 2021.

  • Granahan Investment Management reported no remaining CytomX Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Granahan Investment Management sold 279,218 CytomX Therapeutics shares in Q1 2021, an estimated $1.83M.
  • Granahan Investment Management first reported a position in CytomX Therapeutics in Q4 2017 and held it in 13 quarters.
  • Granahan Investment Management's CytomX Therapeutics position peaked at $4.63M in Q1 2018.
  • 126 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2021.

Based on Granahan Investment Management's 13F filing for Q1 2021, filed 17 May 2021.